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Challenge of Xenotransplantation
in Pediatric Heart Transplantation
Norihide Fukushima, Motohiro Kawauchi, Francois Bouchart,
Sandra Nehlsen-Cannarella and Leonard L. Bailey
Abstract
Although surgical techniques have progressively improved in the field of con-
genital heart disease (CHD), even such as hypoplastic left heart syndrome, pediatric
heart transplantation is the most effective surgical option for complex CHD and
cardiomyopathy with severe heart failure. However, even now, donor heart avail-
ability has been poor in children. Although technologies for ventricular assist device
(VAD) have been progressing even in children, VAD cannot grow as the pediatric
recipient grows. Therefore, pediatric cardiac xenotransplantation has a great possi-
bility to save and grow children with end-stage heart failure. In this chapter, I
would like to introduce the first pediatric baboon-to-human heart transplantation
and its basic animal experiments done by Bailey’s group and the following attempts
for pediatric cardiac orthotopic xenotransplantation (rhesus monkey-to-baboon
and pig-to-primate combination).
Keywords: concordant and discordant xenogeneic orthotopic heart transplantation,
pediatric heart transplantation, clinical trial, antibody absorption, primates, pig,
goat, lamb
1. Introduction
Clinical heart transplantation (HTx) was the unambiguous goal of the laboratory
research at Stanford University in the mid-1960s [1]. They were making tremen-
dous progress in their understanding of the host immune response, and how to
control that response with drugs of that era, while at the same time avoiding lethal
infection. Then, unexpectedly, on December 3, 1967, Christiaan Barnard et al.
performed the first clinical HTx in Cape Town, South Africa [2]. Their recipient
survived only 18 days, dying of pneumonia. Nevertheless, it stirred worldwide
enthusiasm for HTx, and, more importantly, it opened the door for the Stanford
group to develop the procedure in human.
But with regard to infants, Adrian Kantrowitz at New York attempted HTx in a
newborn from an anencephalic baby just 3 days after Barnard’s first HTx [3]. The
recipient died 6 and a half hour after the procedure, and Kantrowitz never pursued
clinical HTx. In the 1970s, there have been great progresses in medical and intensive
management and surgical technology for neonates and infants with complex con-
genital heart. However, almost all neonates and infants with too complexed con-
genital anomaly, especially hypoplastic left heart syndrome (HLHS), could not
survive surgery. Theoretically, these neonates, with naïve immune systems and
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uniformly lethal heart disease, should be excellent candidates for HTx that included
aortic arch reconstruction. But around for a decade since the first HTx, clinical HTx
was limited to only a handful of progressive institutions, and none was
spearheading research in neonatal HTx except a little Leonard L Bailey’s group at
Loma Linda University.
His laboratory was using neonatal goats as recipients, and, initially, goats as
donors. In 1981, the Sandoz Laboratory, a pharmaceutical house in Basal, Switzer-
land, agreed to provide them with an investigational agent called cyclosporine-A
(CsA). With CsA immunosuppression alone, they observed remarkable survival,
maturation, and reproductive capacity among goats that were orthotopically
transplanted as newborns with allografts [4]. Even recipients of cross-species grafts
from lamb to goat experienced unprecedented survival [5].
2. Lamb to goat orthotopic concordant xenoHTx
Fourteen newborn (less than 7 days old) goats underwent orthotopic HTx
with a size-matched lamb’s heart [5]. Ten goats survived longer than 24 hours
after HTx. Recipient animals received CsA 48 and 24 hours before HTx and daily
after HTx on a gradually reducing daily protocol. Recipients were also given pulse
doses of methylprednisolone (100 mg/kg) and azathioprine (3 mg/kg) once a week,
the dosage schedule being gradually reduced. Azathioprine was discontinued on
postoperative day 60. Survival among the 10 recipients was 24, 32, 44, 47, 60, 60,
78, 90, 120, and 165 days. Average survival was 72 days. Serial left ventricular
ejection fractions measured by radionuclide left ventriculography from 1 to
4 months postoperatively in four recipients averaged 50, 58, 45, and 45%. There
were no significant infections. Most animals showed mild-to-moderate subacute
and chronic graft rejection at autopsy. One host showed no gross or microscopic
graft rejection at autopsy on postoperative day 47. Tumor was not observed.
These data suggest that long-term survival may be feasible for newborn recipients
of cardiac xenografts with CsA therapy and limited supplemental
immunosuppression.
3. Attempt of a baboon-to-human orthotopic concordant xenoHTx
Neonatal and small infant heart donors were not available in the early 1980s;
hence, the Bailey’s group focused on the possibility of using immature baboons as
donors for neonates with HLHS. They purchased a panel of infant baboons and
studied them extensively for infectious diseases. They performed HLA-typing, two-
way mixed lymphocyte cultures, and ex vivo perfusion studies to assess their
compatibility with human neonates. They thought it might be possible to actually
select a “best” baboon donor for any individual baby with HLHS. They began an
arduous 14-month process of obtaining Institutional Review Board (IRB) approval
for experimental clinical trials of baboon-to-human baby concordant xenoHTx.
Sandra Nehlsen-Cannarella, a transplant immunologist and Medawar protégé, was
one of external reviewers, helped their works, and finally joined their team after the
IRB was approved in October 1984 [6].
Then, in late July of 1984, Dr. Magdi Yacoub and his team at the National Heart
Hospital in London transplanted an 11-day-old newborn with HLHS [7], but the
recipient had a complex postoperative course and died of respiratory failure on
postoperative day 4. Later that same year, in October, the Bailey’s group were
confronted with the potential to activate our IRB-approved protocol. A neonate
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with HLHS named “Baby Fae”was transplanted on October 26, 1984, with the heart
of a highly selected infant baboon [8, 9]. She lived for only 20 days, and despite
careful observations and analysis, the cause(s) of her death remains somewhat of an
enigma. She did heighten awareness, however, and her transplant led directly to the
first successful neonatal HTx, again as treatment for HLHS, in November of 1985.
That infant is now a 34-year-old man working in Las Vegas. Baby Fae’s legacy is
found among the hundreds of neonates and small infants who are living today
because of primary or secondary HTx in the world. However, donor shortage had
been still severe, and continuous experimental efforts to achieve clinical infant
xenoHTx had been performed in the Bailey’s group.
4. The immunological effects of concordant xenograft bridging to
cardiac allografting in baboon
Human neonatal xenoHTx evolved around the idea of xenograft bridging to
cardiac allografting. The important question relating to this approach was whether
the bridged recipient would develop an antibody response to the initial xenograft
that would be cross-reactive with the allograft donor. This question was initially
explored by Alonso de Begona [10] using a heterotopic HTx model from African
green monkey to juvenile baboons treated with CsA (Table 1). These 5 grafts are
rejected over a period of 5–65 days. Lymphocytotoxic xenoantibody was identified
in recipient blood samples. The rejected xenografts were removed, and the recipient
circulating xenoantibody titers were observed to peak over 24–48 hours. Using
cardiopulmonary bypass primed without blood, the immature baboon recipients
then underwent orthotopic allogeneic HTx and were treated with varying degrees
using a cyclosporine (CSA) protocol. All survived the secondary allogeneic HTx
without any evidence of hyperacute, antibody-mediated rejection. The recipients
survived 10, 58, 65, 198, and 164 days. Despite a high titer of circulating
xenoantibody in each of the host baboons, orthotopic allogeneic engraftment was
possible in all five recipients. Each was immunosuppressed with gradations of CSA-
based therapy. Survival to 5 and 6 months of the last two consecutive animals
(which were ultimately euthanized) was not unlike that expected for
Cardiac heterotopic xenograft
(African green monkey)
Cardiac orthotopic allograft (common olive baboon)
Therapya Rescue
therapy
Survival
(days)
Therapya Rescue
therapy
Survival
(days)
Allograft
rejection
1 A None 11 A None 10 Severe
2 A None 5 A B 58 Moderated to
severe
3 A None 6 A B 65 Moderated to
severe
4 A + B B + C 13 A B + C 198b None
5 A + B + C None 65 A + B None 164b None
aImmunosuppression. (A) cyclosporine + azathioprine + solumedrol; (B) goat anti-human T cell IgG; (C)
monoclonal antibody.
bElectively euthanized.
Table 1.
Survival of xenografts and allografts and host therapy employed in a xenograft bridge to allograft model using
an immature baboon recipient.
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allotransplanted hosts. Xenoantibody did not appear to alter acute or chronic sur-
vival of baboon recipients managed with a clinically applicable regimen of immune
regulation. The two chronic survivors had well-functioning allografts that were free
of significant rejection injury. These findings have subsequently been confirmed
and elaborated on by Michler et al. [11].
5. Rhesus monkey to baboon orthotopic concordant xenoHTx
Orthotopic concordant xenotransplantation in a juvenile primate model was
examined [12, 13]. Eighteen donor rhesus monkeys weighing 2.4–3.8 kg (mean
2.9 kg) were matched with juvenile baboons, aged 9–19 months (mean 12.7 months)
and weighing 3.2–4.8 kg (mean 3.9 kg), using ABH blood type and mixed lympho-
cyte culture. In order to examine plasma level of tacrolimus (Tac) in infant baboons
and establish immunosuppressive regimen before starting orthotopic xenoHTx
experiments [14], seven of these baboons already received two courses of 4-week
immunosuppressive therapy prior to HTx. All baboons underwent splenectomy at
the time of HTx.
Twelve animals were divided into three groups; five baboons received no
immunosuppressive therapy (Group-C). Five baboons were pretreated (Group-P)
and the other seven (Group-NP) was not pretreated. Twelve baboons received
sheep antilymphocyte globulin (ALG; IV 15 mg/kg) induction for 3 days before the
operation and 5 days after xenoHTx and oral tacrolimus (Tac; 18 mg/kg) and
intravenous methotrexate (MTX; 0.1–5 mg IV twice weekly) daily after xenoHTx.
The baboons in Group-P received two courses of 4-week immunosuppressive ther-
apy prior to xenoHTx; the first course consisted with Tac (18 mg/kg p.o. daily)
alone and the second one consisted with Tac (12 mg/kg p.o. daily) and methotrexate
(MTX; 25 mg IV weekly). Pretreated baboons had drug-free intervals for 37 days
between two courses and for 83–110 days between the second course and xenoHTx.
Intravenous methotrexate, methylprednisolone, ALG, and their combination were
used as rescue therapy (Table 2).
Baboons in group-C had a mean survival of 8 days; all died as a result of classic
severe cellular rejection. Baboons in Group-NP had a mean survival of 51.3 days
(25–75 days), and those in Group-P had a mean survival of 198 days (35–502 days).
Two in Group-NP died during rescue therapy for rejection, and three in
Group-NP and two in Group-P died of cytomegalovirus (CMV) infection. One in
Group-NP died of massive micro-pulmonary embolism. The remaining two
in Group-P died of Klebsiella pneumoniae and renal failure aggravated by
ganciclovir, respectively.
The longest surviving baboon, named Max, had been a healthy, active, growing
baboon with normal cardiac function assessed by echocardiography and left
ventriculography and coronary arteries normal in size and distribution assessed by
coronary arteriograms at 1 year after xenoHTx. After these examinations, we tried
to convert him to oral medications, and his level of immunosuppression fluctuated
widely, which led to a late, powerful rejection response. This xenograft rejection
was reversed successfully using corticosteroids and ALG. The additional bolus
immunosuppression, however, permitted the development of generalized CMV
disease and eventually bacterial sepsis from which Max (Figure 1) ultimately died.
The animal’s autopsied xenograft was almost free of cellular rejection but with mild
coronary graft atherosclerosis [15].
Management of CMV infection in this splenectomized series of baboon recipi-
ents proved to be at least as difficult as controlling the immune response toward
their cardiac xenografts. However, Tac coupled with low-dose maintenance
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methotrexate and splenectomy has produced prolonged host survival in this
xenotransplantation model. Results suggest that concordant xenotransplantation
would be a suitable biologic bridge to allotransplantation.
Survival
(days)
Histological findings of
autopsied xenograft
Rescue therapy (onset day after
transplant)
Cause of death
Group-Ca
1 6 Moderate cellular rejection None Rejection
2 7 Moderate cellular rejection None Rejection
3 8 Severe cellular rejection None Rejection
4 8 Severe cellular rejection None Rejection
5 9 Severe cellular rejection None Rejection
6 10 Severe cellular rejection None Rejection
Group-NPa
1 25 CMV infection, no rejection ALG (21) Systemic CMV
infection
2 32 CMV infection, no rejection None CMV infection
(graft)
3 43 Cellular infiltration to
coronary arteries
None CMV infection
(lung, kidney)
4 53 Mild cellular rejection ALG (68) CMV infection
(lung)
5 57 Mild cellular rejection ALG +MP (13), Upb Tac + ALG +MP
(38)
During rejection
treatment
6 74 Mild cellular rejection Mild
graft atherosclerosis
Upb MTX (25) Pulmonary
embolism
7 75 Mild cellular rejection ALG + MP (29, 62) During rejection
treatment
Group Pa
1 35 Mild cellular rejection None Klebsiella
pneumonia
2 96 No rejection ALG + MP (71) Renal failure
3 123 Patchy fibrosis in septum and
inferior wall
None CMV infection
(lung, kidney)
4 234 Toxoplasmosis ALG (94d) Toxoplasmosis
5 502 Mild cellular rejection Mild
graft atherosclerosis
Upb Tac and MTX (68, 238),
ATGAM+MP (392), MP (482)
Liver failure and
CMV infection
ALG, sheep antilymphocyte globulin; CMV, cytomegalovirus; MP, methyl prednisolone; Tac, tacrolimus; MTX,
methotrexate; ATGAM, equine anti-thymocyte globulin.
aGroup-C: controls. Group-NP: intravenous sheep antilymphocyte globulin (ALG) induction at 3 and + 5 days
perioperatively, daily oral tacrolimus (Tac), and twice weekly intravenous methotrexate (MTX) after
transplantation. Group-P: two courses of 4-week immunosuppressive therapy (1st course, oral Tac alone; 2nd course,
oral Tac and intravenous MTX) prior to transplantation and the same immunosuppressive therapy after
transplantation as for Group-NP.
Groups NP and P subjects had splenectomy at the time of heart transplantation.
bincrease dose.
Table 2.
Results of orthotopic cardiac xenotransplantation between immature baboon recipients and rhesus monkey
donors.
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6. Toward discordant xenoHTx
Although the high degree of evolutionary relatedness between human beings
and primates both suggests that xenotransplantation of primate organs and tissue
might be successful, particular concerns are raised by the use of primates, such as
baboons. The characteristics, for example, of intelligence and complex social inter-
actions of these closely related higher primates appear to be so like those of human
beings that use members of those species as sources for xenotransplantation which
might well be seen as ethically unacceptable [16]. The potential risk of extinction,
even to a species like the baboon that is not currently endangered, must be taken
seriously. The possible transmission of disease from higher primates to human
beings and the welfare of the animals should be concerned. From these concerns, it
is currently agreed that the use of primates would be ethically unacceptable.
Given the ethical concerns raised by the use of primates for xenotransplantation,
attention has turned to developing the pig as an alternative source of organs and
tissue, because the use of pigs for xenotransplantation raises fewer ethical concerns.
Attention has focused in particular on pigs, since their organs are comparable in size
to human ones, and they breed rapidly and could thus be used to supply transplant
material on a large scale. The use of pigs as a domestic animal that is farmed and
eaten is long established, and many would have fewer concerns about their use for
xenotransplantation than the use of primates. If pigs are used for xenotransplanta-
tion, they are likely to have been genetically modified so the human immune
response to the pig organs and tissue is reduced [16].
When a pig organ is transplanted into a human or nonhuman primate, an imme-
diate immune response occurs with hyperacute rejection (HAR). This has been
defined as destruction of the graft in less than 24 hours; however, it usually occurs
Figure 1.
Max, an immature baboon recipient of an orthotopic cardiac xenotransplant acquired from a donor rhesus
monkey.
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within the first hour. This is due to the binding of the preformed anti-pig antibodies
(Ab) to the endothelial cells of the graft. Ab deposits initiate a complement-mediated
response with endothelial injury, resulting in thrombosis, interstitial hemorrhage, and
edema, with subsequent graft dysfunction [17]. Later, it was determined that Ab bind
to the carbohydrate epitope, galactose–a1,3-galactose (Gal), expressed in the pig
vascular endothelium. This oligosaccharide is present in other mammals, except
humans and primates. These Ab are produced in response to viruses and microor-
ganisms that express Gal and colonize the gastrointestinal tract of primates [18].
7. Pig-to-baboon orthotopic discordant xenoHTx
The feasibility of transplanting across discordant xenogeneic barriers in an
orthotopic newborn pig-to-juvenile baboon model was first explored in the Bailey’s
Treatment Survival
(hours)
Pathology of autopsied
xenograft
Cause of
death
Lung
perfusion
Exsanguination
Group-Ca
1b None None 4.5 HAR Rejection
2 None None 18 HAR Rejection
Group-Da
1c Donor lung None 6.5 HAR Rejection
2 Donor lung None 10 HAR Rejection
3d Donor lung None 375 Mild DXR and GCAS CMV
infection
Group-LDa
1 Large pig
lung
None 99 Pneumonia Pneumonia
2 Large pig
lung
None 111 DXR Rejection
Group-D + Ea
1 Donor lung Blood replacement 117.5 DXR Brain death
2c Donor lung RBC/serum
replacement
100 DXR Rejection
3 Donor lung RBC/serum
replacement
111 DXR Rejection
4 Donor lung RBC/serum
replacement
123 DXR Rejection
5 Donor lung RBC/serum
replacement
174.5 DXR, CR Rejection
aGroup-C, controls; Group-D, donor lung perfusion; Group-LD, perfusion with another large pig lungs; Group-
D + E, donor lung perfusion, exsanguination, and replacement with whole blood pretreated or packed red blood cell
(RBC) and serum pretreated.
bNo immunosuppression therapy.
cKidney perfusion in case of suspected antibody-mediated rejection.
dThymic injection with donor myocardium (left atrium).
All subjects had pretransplant splenectomy. CMV, cytomegalovirus; RBC, red blood cell; HAR, hyperacute rejection;
DXR, delayed xenograft rejection; CR, cellular rejection.
Table 3.
Results of orthotopic cardiac xenotransplantation between juvenile baboon recipients and piglet donors.
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laboratories during the early 1990s. Because HAR was at that time the single
most important factor in limiting discordant xenoHTx, early strategies were
directed toward eliminating or reducing baboon preformed xeno Ab to pig sugar
antigens [19, 20].
All recipient baboon underwent splenectomy 2 weeks before HTx. Donor hearts
were obtained from 12 newborn piglets of either sex age 2–7 days and weighing 1.8–
3.1 kg (mean 2.3  0.1 kg) and transplanted orthotopically with deep hypothermia
and circulatory arrest in recipient juvenile baboon age 252–459 days (mean
362 19 days) and weighing 2.4–3.5 kg (mean 2.9 0.1 kg). All animals received an
infusion of nafamostat mesylate (FUT-175) at a dose of 2 mg/kg/h for 2 h at the time
of reperfusion. The recipient baboon received 15 mg/kg CsA orally or 5 mg/kg
intravenously and 5 mg/kg 15-deoxyspergualin (DSG) intramuscularly, from the
day before HTx until death.
In two baboons, no antibody adsorption (AbA) using pig lungs was performed
for control (Group-C). In 10 baboons, the blood in the bypass circuit was perfused
into a pig lung to absorb baboon anti-pig antibody during circulatory arrest at the
time of HTx. In three baboons (Group-D), the donor lung was perfused, and in two
baboons (Group-LD), a lung larger than the donor pig (weighing 5–7 kg) was
perfused. In five baboons (Group-D + E), the donor lung was perfused, and exsan-
guination was also performed at the beginning of cardiopulmonary bypass (CPB),
and the baboon blood was replaced with pretreated whole blood (N = 1) or packed
red blood cell (RBC) and 50 ml of pretreated plasma (N = 4). The pretreated blood
(N = 1) and serum (N = 4) were made by perfusing with other large pig lung
(weighing 15 and 20 kg) before xenoHTx. Two baboons underwent pig kidney
perfusion using an extracorporeal shunt from the right femoral artery to vein, 5 and
6 days after xenoHTx, because antibody-mediated rejection was suspected.
Figure 2.
An immature baboon recipient of an orthotopic cardiac xenotransplant acquired from a donor pig, which
survived 6 days after xenotransplant.
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The two control animals survived 4.5 and 18 hours, and the pathological changes
of the grafts were compatible with HAR. The other animals survived 125  33 h
(10–375 hors). The longest surviving baboon who survived 375 hours was in Group-
D, but other two in Group-D died of HAR. All baboons in Group-LD and Group-
D + E survived more than 4 days after XenoHTx. One in Group-D died of CMV
infection and one in Group-LD died of pneumonia. One in Group-LD and four in
Group-D + E died of acute cellular rejection. In summary, examination and echo-
cardiography revealed no evidence of hyperacute rejection in baboons surviving
more than 1 day. The longest survivor (375 hours) died of CMV infection with
microscopic evidence of mild delayed HAR and graft coronary atherosclerosis. A
variable amount of delayed xenograft rejection (DXR) was observed histologically,
among the other recipient baboons (Table 3 and Figure 2) [20].
Another baboon which underwent large pig lung perfusion and is given
Tac + MTX without splenectomy survived 16 days, and the autopsied graft showed
mild DXR and moderate GCAS [20].
8. The role of anti-pig antibody in pig-to-baboon xenoHTx rejection
To investigate the role of anti-pig Ab in discordant xenograft rejection, these 12
baboons were divided into 2 groups: Group-S (n = 4) died within 24 hr. of HTx and
Group-L (n = 8) survived more than 24 hr. [19]. Mean survival period was
9.8  3.0 h in Group-S and 151  33 h in Group-L. Baboon anti-pig Ab was
measured before CPB, before circulatory arrest, during AbA, at the end of CPB, and
daily after HTx. Anti-RBC Ab was measured by the titration method at tempera-
tures of 4 degrees C and 37 degrees C (RAb-4 and RAb-37). Anti-endothelial cell Ab
(EAb) and anti-white blood cell Ab (WAb) titers were measured with enzyme-
linked immunosorbent assay (ELISA). RAb titration > or = 1/4 and EAb and
WAb > or = 1/256 were determined to be seropositive. Seropositive rate of RAb-37
at the end of CPB (endCPB) in Group-L was significantly higher than that in
Group-S (8/8 vs. 1/4; P < 0.05). The seronegative rates of RBC-4 and EAb
(endCPB) in Group-L were higher than those in Group-S (7/8 vs. 1/4 and 6/8 vs.
1/4, respectively), but not significantly. There was no difference in seronegative
rate of WAb (endCPB) between both groups. More than fourfold decrease in RAb-4
and RAb-37 by AbA with a pig lung was observed in 5 and 7 of 8 baboons, while EAb
and WAb did not change by AbA. In all of Group-L, RAb-4 reverted to seropositive
within 3 days after HTx. In four of Group-L, RAb-37 became S(+), 1 or 2 days
before death by rejection. EAb became seropositive in all of Group-S, but five of
them survived more than 5 days after seroconversion. It was concluded that a pig
lung absorbed RAb-4 and RAb-37 may play a role in DXR.
After I came back to Japan, the role of RAb-37 on pig-to-baboon xenoHTx was
investigated using sequential heterotopic HTx [21]. Fifteen pig hearts were
obtained from pigs weighing 6.4–91 kg. Eleven hearts from pigs larger than the
recipient were used for perfusion, and four hearts from a pig of the same size as
the recipient for heterotopic transplant donor heart. Four female baboons
weighing 5.9–8.1 kg received Tac (12 mg.kg) and CAM (50 mg/kg) p.o. daily
2 weeks before and after xenoHTx. After perfusion with two or three large pig
hearts, a pig heart was heterotopically transplanted in the right neck of recipient
baboon. As the second and third recipient baboons died of hypotension during the
third pig heart perfusion and could not undergo heterotopic xenoHTx, the last
baboon underwent two pig heart perfusion and subsequent heterotopic xenoHTx.
All first perfused hearts and two second perfused hearts were hyperacutely
rejected within 30 minutes of perfusion, but the other two second and all third
9
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RAb-4 RAb-37 EAb-IgM EAb-IgG
Adult 582  579 296  291 288  189 853  264
Cord blood 144  181* 69/96* 21  8.3** 683  264
Infant <38 days old 80  58* 30  19*
Infant > = 38 days old 689  678*** 239  149***
RAb-4 and RAb-37: human anti-pig red blood cell antibody titer at temperature of 4°C and 37°C, respectively.
EAb-IgM and EAb-IgG: human anti-pig endothelial cell antibody (immunoglobulin M and G) titers, respectively.
*p < 0.01 vs. adult.
**p < 0.05 vs. adult.
***p < 0.01 vs. cord blood or infant younger than 38 days old.
Table 4.
Human anti-pig antibody against red blood cell and endothelial cell.
Treatment Survival after
releasing AXC
(minutes)
Off CPB and
chest
closure
Extubation Pathology of
autopsied
xenograftDonor pig DAF pig
organ
perfusion
Group-Ca
1b F1 pig None 21 No No Severe HAR
2 F1 pig None 132 Yes No Severe HAR
Group-DAFa
1 c DAFb
transgenic pig
None 104 Yes No Mild HAR
2 DAFb
transgenic pig
None 135 Yes Yes Mild HAR
3 DAFc
transgenic pig
None 126 Yes Yes Mild HAR
Group-DAF+Pa
1 DAFb
transgenic pig
Heart 211 Yes No Moderate HAR
2 DAFb
transgenic pig
Heart 310 Yes No Moderate HAR
3 d DAFb
transgenic pig
Lung 305 Yes Yes Mild HAR
Group-GnT-IIIa
1 GnT-III
transgenic pig
None 73 Yes No Mild to
moderate HAR
2 c GnT-III
transgenic pig
None 257 Yes Yes Mild to
moderate HAR
3 GnT-III
transgenic pig
None 493 Yes Yes Mild to
moderate HAR
DAF, decay-accelerating factor; GnT-III, beta-D mannoside beta-1,4-N-acetylglucosaminyltransferase III; AXC,
aortic cross-clamping; CPB, cardiopulmonary bypass; HAR, hyperacute rejection; DXR, delayed xenograft rejection.
aGroup-C, controls; Group-DAF, transplanted DAF transgenic pig heart; Group-DAF + P, transplanted DAF
transgenic pig heart and perfused with another pig heart; Group-GnT-III, transplanted GnT-III transgenic pig heart.
bHetero DAF transgenic pig.
cHomo DAF transgenic pig.
Table 5.
Results of orthotopic cardiac xenotransplantation between rhesus monkey recipients and transgenic pig donors.
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perfused hearts were not rejected within 2 hours after perfusion. The first and last
transplanted pig hearts stopped beating 6 days and 18 hours after xenoHTx.
Histological examination showed no rejection findings in the myocardium of the
graft taken at 1 hour after xenoHTx, but the explanted grafts after cardiac arrest
showed massive necrosis with ischemic change which suggested some kinds of
DXR. RAb-37 prior to perfusion in all baboons was 1: 256 or 1:512, but that at
1 hour after XenoHTx was less than 1:4 which was considered to be negative.
These findings suggested that RAb-37 may play an important role in DXR in pig-
to-baboon combination.
We also investigated the differences between newborn and adult natural het-
erophile anti-pig red blood cell IgM xenoantibodies as correlates of xenograft sur-
vival [22] (Table 4). Newborns and younger infants have significantly lower titers
of anti-pig RAb-4 and RAb-37 and anti-pig EAb-IgM than adult.
After coming back to Japan, Kawauchi M also investigated ontogeny of RAb-37
and HAR in 15 macaque monkeys [23]. Ten hearts from newborn Gottingen minia-
ture swine (6–12 days old) were heterotopically transplanted into 10 infant
macaque monkeys (52, 59, 75, 101, 108, 114, 129, 151, 181, and 192 days old) without
immunosuppressive therapy. RAb-37 prior to xenoHTx were gradually increased
according to the age of the monkeys. All six donor hearts in the recipients younger
than 4 months survived 6 hours, and then the animals were killed while the donor
hearts were beating. Donor hearts in four infant recipients ages 129, 151, 181, and
192 days were hyperacutely rejected at 19, 22, 29, and 9 minutes. The pig hearts in
the recipients younger than 4 months showed no findings of HAR.
These two findings may suggest that newborn and younger infants may be more
suitable recipient of discordant xenoHTx.
9. Transgenic pig-to-rhesus monkey orthotopic discordant xenoHTx
As Miyagawa et al. demonstrated the effect of the human beta-D mannoside
beta-1,4-N-acetylglucosaminyltransferase III (GnT-III) gene in downregulating the
xenoantigen of pig heart grafts, using a pig to cynomolgus monkey transplantation
model suggests that this approach may be useful in clinical xenotransplantation
in the future [24]. Moreover, they showed the possibility that both the
decay-accelerating factor (DAF) and GnT-III double transgenic pig skin xenografts
could be used in place of human skin allografts in the cases of severe burns [25].
Then, after coming back to Japan, the author and Japanese colleagues
underwent orthotopic discordant xenoHTx using DAF and GnT-III transgenic pig
heart xenografts (unpublished data). Donor hearts were obtained from two F1 pigs,
six DAF transgenic pigs (five hetero DAF and one homo DAF), and three GNT-III
transgenic pigs and transplanted orthotopically in adult rhesus monkey with deep
hypothermia and circulatory arrest. All animals received no immunosuppressive
drugs.
In two baboons, a F1 pig heart was transplanted for control (Group-C). In three
baboons, the blood in the bypass circuit was perfused into a hetero DAF pig heart or
lung to absorb baboon anti-pig antibody during circulatory arrest at the time of
xenoHTx (Group-DAF + P).
In the one control animal, the graft stopped beating 21 minutes after aortic
unclamping before weaning from cardiopulmonary bypass (CPB). All other 10
rhesus monkeys could wean from CPB and undergo chest closure, but only one in
Group-DAF, one in Group-DAF + P, and two in Group-GNT-III could be removed
from a ventilator. Two grafts in Group-C and two perfused pig hearts showed
severe HAR. Other grafts showed various degree of HAR. These data suggested that
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transgene of DAF or GNT-III might not be enough to suppress HAR in adult rhesus
monkey which had high titers of anti-pig xenoantibodies.
10. Recent concerns about xenotransplantation in children
Xenotransplantation has been proposed as a method of reducing the espe-
cially acute shortage of organs for babies and children. Early clinical trials of
xenotransplantation will be a form of therapeutic research. Therapeutic research
must offer some prospect of genuine benefit for the patient, but it involves
greater uncertainties than treatment, and therefore greater caution must be
exercised. Many working parties concerning xenotransplantation, such as the
British Pediatric Association and the Medical Research Council, have advised
that therapeutic research should not involve children if it could equally well be
performed with adults. It would be difficult to justify the involvement of chil-
dren in major and risky xenotransplantation trials before some of the uncer-
tainties have been eliminated in trials involving adults. Therefore, the FDA and
WHO also recommend that the first xenotransplantation trials involve adults
rather than children.
Then, although the authors tried to continue animal experiment to start clinical
pediatric xenoHTx in the mid-2000s, we resigned.
11. Current status of pediatric heart transplantation in the world and
Japan
After the Bailey’s first xenoHTx, hundreds of neonates and small infants with
end-stage heart failure are living today because of primary or secondary HTx in the
world. The number of pediatric HTx has been increasing (Figure 3), and their
survival has been acceptable in every recipient age (Figure 4).
When the author came back to Japan in 1994, there was no Transplant Act in
Japan. In 1988, the Japan Medical Association professed that it would accept brain
death as human death. In 1990, the Provisional Commission for the Study on
Figure 3.
Pediatric heart transplants. Recipient age (in years) distribution by year of transplant.
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Brain Death and Organ Transplantation was set up in 1990. The draft of the
Organ Transplantation Law was proposed in 1994. Finally, on October 16, 1997,
the Organ Transplant Act took effect, which enabled brain dead organ donation
only if the person expressed in writing prior to death his/her intent to agree to
donate his/her organs. In addition, the Act states that “only persons 15 years and
above can express to donate.” Then, heart transplants to small children become
impossible.
So, we started to send children with end-stage heart failure to Dr. Bailey as
other pediatricians did (Figure 5) and continued to perform xenoHTx experi-
ments. But as mentioned above, we finished experiments due to the FDA and
WHO recommendation against pediatric xenotransplantation. Since 2003, the
author and members of Japanese Associations of Transplant patients made many
efforts to revise the Act, and finally the Act was revised in 2010. After then, the
Figure 5.
Pediatric heart transplant in Japan.
Figure 4.
Pediatric heart transplants. Kaplan–Meier survival (transplants: January 1982–June 2016).
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number of pediatric HTx has increased and finally exceeded that of HTx abroad
(Figures 5 and 6).
Unexpectedly, Dr. Bailey (Figure 7) died of cancer in May 2019.
Figure 7.
The panel of Professor Leonard Bailey’s memorial service.
Figure 6.
Pediatric heart transplantation abroad from Japan.
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